UK Lucentis Biosimilar Nod Offers Teva Potential First-Mover Advantage
Formycon-Bioeq Partnered Ongavia Receives First European Approval In UK
Teva is gearing up to introduce the Ongavia ranibizumab biosimilar in the UK, following an approval by the local regulator ahead of its European counterpart. The development means the Israeli firm and partners Bioeq and Formycon could secure a global first launch of a rival to Lucentis, ahead of expected imminent launches by Samsung Bioepis of its Byooviz version in the US and Europe.
You may also be interested in...
Formycon has completed its acquisition of Athos’ biosimilar candidates for Stelara and Lucentis, following the announcement of the deal in March.
Six of the 10 biosimilar candidates under FDA review are waiting on inspections delayed by COVID-19; in the meantime, sponsors jockey for position when Humira biosimilar launch windows open up next year.
Coherus is laying the pathway for future launches of biosimilars and novel biologics by strengthening its leadership team with a trio of appointments.